Ketamine to enhance methadone treatment retention in patients with opioid use disorder and co-morbid depression

Ketamine to enhance methadone treatment retention in patients with opioid use disorder and co-morbid depression

<p><i>Background:</i> Opioid use disorder (OUD) is a chronic relapsing condition with a high mortality rate. While medications such as methadone are valuable first-line therapies, retention is poor, with the highest dropout rates early in a treatment attempt. Poor outcomes are due...

Full description

Saved in:
Bibliographic Details
Main Author: Peter Manza (8493354) (author)
Other Authors: Annabelle M. Belcher (10014539) (author), Heather Fitzsimons (22109808) (author), Max Spaderna (22109811) (author), Aaron D. Greenblatt (10014536) (author), Hannah C. Smith (16495867) (author), Meghan Derenoncourt (22109814) (author), Donald Gann (22109817) (author), Umer Farooq (1607068) (author), Mark D. Kvarta (22109820) (author), Bethany A. DiPaula (17308771) (author), Sarah Merritt (22109823) (author), Ivana Mitic (22109826) (author), Carlos A. Zarate (4382656) (author), Todd D. Gould (12043243) (author), Eric Weintraub (4689943) (author), Sarah M. Kattakuzhy (22109829) (author)
Published: 2025
Subjects:
Medicine
Neuroscience
Pharmacology
Biotechnology
Cancer
Mental Health
Opioid addiction
antidepressant
clinical trial
autobiographies
medications for opioid use disorder
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items